Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

doi:10.1016/j.immuni.2016.09.009

. 2016 Oct 18;45(4):931-943.

doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

Romain Daillère¹, Marie Vétizou¹, Nadine Waldschmitt², Takahiro Yamazaki³, Christophe Isnard⁴, Vichnou Poirier-Colame¹, Connie P M Duong⁵, Caroline Flament⁵, Patricia Lepage⁶, Maria Paula Roberti⁵, Bertrand Routy¹, Nicolas Jacquelot¹, Lionel Apetoh⁷, Sonia Becharef⁵, Sylvie Rusakiewicz⁵, Philippe Langella⁶, Harry Sokol⁸, Guido Kroemer⁹, David Enot¹⁰, Antoine Roux¹¹, Alexander Eggermont¹², Eric Tartour¹³, Ludger Johannes¹⁴, Paul-Louis Woerther¹⁵, Elisabeth Chachaty¹⁵, Jean-Charles Soria¹², Encouse Golden¹⁶, Silvia Formenti¹⁶, Magdalena Plebanski¹⁷, Mutsa Madondo¹⁷, Philip Rosenstiel¹⁸, Didier Raoult¹⁹, Vincent Cattoir²⁰, Ivo Gomperts Boneca²¹, Mathias Chamaillard², Laurence Zitvogel²²

Affiliations

¹ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, 94270, France.
² University Lille, CNRS, Inserm, CHRU Lille, Institut Pasteur de Lille, U1019-UMR 8204-CIIL, Centre d'Infection et d'Immunité de Lille, 59000 Lille, France.
³ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France.
⁴ Université de Caen Basse-Normandie, EA4655 U2RM (Équipe Antibio-Résistance), Caen, 14033, France; CHU de Caen, Service de Microbiologie, Caen, 14033, France.
⁵ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, France.
⁶ Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, 78350 Jouy-en-Josas, France.
⁷ Lipids, Nutrition, Cancer, INSERM, U866, Dijon, 21078, France; Department of Medicine, Université de Bourgogne Franche-Comté, Dijon, 21078, France; Department of Oncology, Centre Georges François Leclerc, Dijon, 21000, France.
⁸ Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, 78350 Jouy-en-Josas, France; AVENIR Team Gut Microbiota and Immunity, ERL, INSERM U 1157/UMR 7203, Faculté de Médecine, Saint-Antoine, Université Pierre et Marie Curie (UPMC), Paris, 75012, France; Service de Gastroentérologie, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (APHP), Paris, 75012, France.
⁹ INSERM U848, 94805 Villejuif, France; Metabolomics Platform, Institut Gustave Roussy, Villejuif, 94805, France; Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, 75006, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, 75015, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, 75006, France; Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, 17176, Sweden.
¹⁰ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Metabolomics Platform, Institut Gustave Roussy, Villejuif, 94805, France.
¹¹ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, 94270, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, 75006, France.
¹² Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, 94270, France.
¹³ INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, Paris, 75015, France; Service d'immunologie biologique, Hôpital Européen Georges Pompidou, Paris, 75015 France.
¹⁴ INSERM U1143, 75005 Paris, France; Institut Curie, PSL Research University, Endocytic Trafficking and Therapeutic Delivery group, Paris, 75248, France; CNRS UMR 3666, Paris, 75005, France.
¹⁵ Service de microbiologie, GRCC, Villejuif, 94805, France.
¹⁶ Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
¹⁷ Department of Immunology and Pathology, Monash University, Alfred Hospital Precinct, Melbourne, Prahran, Victoria 3181, Australia.
¹⁸ Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
¹⁹ AIX MARSEILLE UNIVERSITE, URMITE (Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes), UMR 7278, INSERM 1095, IRD 198, Faculté de Médecine, Marseille 13005, France.
²⁰ Université de Caen Basse-Normandie, EA4655 U2RM (Équipe Antibio-Résistance), Caen, 14033, France; CHU de Caen, Service de Microbiologie, Caen, 14033, France; CNR de la Résistance aux Antibiotiques, Laboratoire Associé Entérocoques, Caen, 14033, France.
²¹ Institut Pasteur, Unit Biology and Genetics of the bacterial Cell Wall, Paris, 75015, France.
²² Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, 94270, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, France. Electronic address: laurence.zitvogel@gustaveroussy.fr.

PMID: 27717798
DOI: 10.1016/j.immuni.2016.09.009

Free article

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

Romain Daillère et al. Immunity. 2016.

Free article

. 2016 Oct 18;45(4):931-943.

doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.

Authors

Affiliations

¹ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, 94270, France.
² University Lille, CNRS, Inserm, CHRU Lille, Institut Pasteur de Lille, U1019-UMR 8204-CIIL, Centre d'Infection et d'Immunité de Lille, 59000 Lille, France.
³ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France.
⁴ Université de Caen Basse-Normandie, EA4655 U2RM (Équipe Antibio-Résistance), Caen, 14033, France; CHU de Caen, Service de Microbiologie, Caen, 14033, France.
⁵ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, France.
⁶ Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, 78350 Jouy-en-Josas, France.
⁷ Lipids, Nutrition, Cancer, INSERM, U866, Dijon, 21078, France; Department of Medicine, Université de Bourgogne Franche-Comté, Dijon, 21078, France; Department of Oncology, Centre Georges François Leclerc, Dijon, 21000, France.
⁸ Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, 78350 Jouy-en-Josas, France; AVENIR Team Gut Microbiota and Immunity, ERL, INSERM U 1157/UMR 7203, Faculté de Médecine, Saint-Antoine, Université Pierre et Marie Curie (UPMC), Paris, 75012, France; Service de Gastroentérologie, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (APHP), Paris, 75012, France.
⁹ INSERM U848, 94805 Villejuif, France; Metabolomics Platform, Institut Gustave Roussy, Villejuif, 94805, France; Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, 75006, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, 75015, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, 75006, France; Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, 17176, Sweden.
¹⁰ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Metabolomics Platform, Institut Gustave Roussy, Villejuif, 94805, France.
¹¹ Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, 94270, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, 75006, France.
¹² Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, 94270, France.
¹³ INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, Paris, 75015, France; Service d'immunologie biologique, Hôpital Européen Georges Pompidou, Paris, 75015 France.
¹⁴ INSERM U1143, 75005 Paris, France; Institut Curie, PSL Research University, Endocytic Trafficking and Therapeutic Delivery group, Paris, 75248, France; CNRS UMR 3666, Paris, 75005, France.
¹⁵ Service de microbiologie, GRCC, Villejuif, 94805, France.
¹⁶ Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
¹⁷ Department of Immunology and Pathology, Monash University, Alfred Hospital Precinct, Melbourne, Prahran, Victoria 3181, Australia.
¹⁸ Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
¹⁹ AIX MARSEILLE UNIVERSITE, URMITE (Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes), UMR 7278, INSERM 1095, IRD 198, Faculté de Médecine, Marseille 13005, France.
²⁰ Université de Caen Basse-Normandie, EA4655 U2RM (Équipe Antibio-Résistance), Caen, 14033, France; CHU de Caen, Service de Microbiologie, Caen, 14033, France; CNR de la Résistance aux Antibiotiques, Laboratoire Associé Entérocoques, Caen, 14033, France.
²¹ Institut Pasteur, Unit Biology and Genetics of the bacterial Cell Wall, Paris, 75015, France.
²² Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, 94270, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, France. Electronic address: laurence.zitvogel@gustaveroussy.fr.

PMID: 27717798
DOI: 10.1016/j.immuni.2016.09.009

Abstract

The efficacy of the anti-cancer immunomodulatory agent cyclophosphamide (CTX) relies on intestinal bacteria. How and which relevant bacterial species are involved in tumor immunosurveillance, and their mechanism of action are unclear. Here, we identified two bacterial species, Enterococcus hirae and Barnesiella intestinihominis that are involved during CTX therapy. Whereas E. hirae translocated from the small intestine to secondary lymphoid organs and increased the intratumoral CD8/Treg ratio, B. intestinihominis accumulated in the colon and promoted the infiltration of IFN-γ-producing γδT cells in cancer lesions. The immune sensor, NOD2, limited CTX-induced cancer immunosurveillance and the bioactivity of these microbes. Finally, E. hirae and B. intestinihominis specific-memory Th1 cell immune responses selectively predicted longer progression-free survival in advanced lung and ovarian cancer patients treated with chemo-immunotherapy. Altogether, E. hirae and B. intestinihominis represent valuable "oncomicrobiotics" ameliorating the efficacy of the most common alkylating immunomodulatory compound.

PubMed Disclaimer

Comment in

Two Bugs a NOD Away from Improving Cancer Therapy Efficacy.
Araya RE, Goldszmid RS. Araya RE, et al. Immunity. 2016 Oct 18;45(4):714-716. doi: 10.1016/j.immuni.2016.10.007. Immunity. 2016. PMID: 27760335 Review.

Cited by

Resveratrol Modulates the Gut Microbiota and Inflammation to Protect Against Diabetic Nephropathy in Mice.
Cai TT, Ye XL, Li RR, Chen H, Wang YY, Yong HJ, Pan ML, Lu W, Tang Y, Miao H, Snijders AM, Mao JH, Liu XY, Lu YB, Ding DF. Cai TT, et al. Front Pharmacol. 2020 Aug 19;11:1249. doi: 10.3389/fphar.2020.01249. eCollection 2020. Front Pharmacol. 2020. PMID: 32973502 Free PMC article.
Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition.
Lione L, Salvatori E, Petrazzuolo A, Massacci A, Maggio R, Confroti A, Compagnone M, Aurisicchio L, Ciliberto G, Palombo F. Lione L, et al. Oncoimmunology. 2021 Mar 23;10(1):1898832. doi: 10.1080/2162402X.2021.1898832. Oncoimmunology. 2021. PMID: 33796408 Free PMC article.
Microbiome in Cancer Development and Treatment.
Ciernikova S, Sevcikova A, Mladosievicova B, Mego M. Ciernikova S, et al. Microorganisms. 2023 Dec 22;12(1):24. doi: 10.3390/microorganisms12010024. Microorganisms. 2023. PMID: 38257851 Free PMC article. Review.
High carbohydrate diet decreases microbial diversity and increases IL-1β levels in mice colon.
Ulutas MS, Aydin E, Cebeci A. Ulutas MS, et al. Food Sci Biotechnol. 2024 May 4;33(9):2201-2211. doi: 10.1007/s10068-024-01581-5. eCollection 2024 Jul. Food Sci Biotechnol. 2024. PMID: 39130660
Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
Zou R, Wang Y, Ye F, Zhang X, Wang M, Cui S. Zou R, et al. Clin Transl Oncol. 2021 Nov;23(11):2237-2252. doi: 10.1007/s12094-021-02637-2. Epub 2021 May 17. Clin Transl Oncol. 2021. PMID: 34002348 Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

R01 CA161879/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
Molecular Biology Databases
- Mouse Genome Informatics (MGI)
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

Affiliations

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

Authors

Affiliations

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials